Guide

Blood, Tissue & Cell Therapy Readiness: One Spine Across Eight Frameworks

Blood centres, tissue establishments, cord blood banks, and cellular therapy manufacturers all sit inside the same regulatory family but rarely on the same operating system. A US blood bank runs under 21 CFR 600/606/610/630 and the AABB Standards. A tissue establishment runs under 21 CFR 1271 with CGTP. An EU tissue bank runs under Directive 2004/23/EC and its technical annexes. A cord blood bank runs under both 1271 and (if licensed) 21 CFR 610 BLA requirements. A CAR-T manufacturer runs under 21 CFR 211 GMP, 21 CFR 1271 starting material requirements, and FACT-JACIE for the clinical site. This hub maps the eight readiness paths V5 supports and links to the detailed spoke guides — so a programme that grows across modalities does not re-build its QMS each time.

Start free trial Free trial, no credit card, onboard in days, not months.

The framework family and why one spine matters

Blood, tissue and cell therapy regulation shares a common DNA — donor eligibility, traceability donor-to-recipient, cross-contamination prevention, deviation and adverse reaction reporting, and a long retention horizon (10+ years). The frameworks diverge on the boundary tests (361 vs 351 for HCT/Ps), the accreditation overlay (AABB, FACT-JACIE, NetCord-FACT), the regional rule set (EU Directive 2004/23 vs FDA 1271), and the GMP overlay where the product is regulated as a biologic (CAR-T, gene-modified cells, licensed cord blood). A QMS that handles each as a separate silo duplicates effort and breaks down at the boundaries — exactly where inspections live.

The eight readiness paths and where to start

Path 1 — Blood bank cGMP: 21 CFR 606 + AABB Standards. Path 2 — Blood establishment licensure: 21 CFR 600/610/630 with BLA. Path 3 — HCT/P tissue: 21 CFR 1271, 361 vs 351 boundary, CGTP. Path 4 — EU tissue/cells: Directive 2004/23/EC + technical Directives 2006/17 and 2006/86. Path 5 — Cord blood bank: 21 CFR 1271 + (if licensed) 21 CFR 610 BLA. Path 6 — Cellular therapy clinical site: FACT-JACIE accreditation. Path 7 — CAR-T manufacturing: 21 CFR 211 GMP + 1271 starting material + FACT-JACIE handoff. Path 8 — Donor eligibility, look-back and deviation: cross-cutting, applies to all paths. Start with the path that owns your inspection — then layer the overlays your product lines require.

The boundary that decides the path: 361 vs 351 and the GMP overlay

The single highest-stakes decision is the 361 vs 351 boundary under 21 CFR 1271.10 — minimal manipulation, homologous use, no combination, and the autologous/systemic effect test. A 361 HCT/P runs under CGTP (Subpart D of 1271). A 351 HCT/P is regulated as a biologic and runs under 21 CFR 211 GMP plus the biologic licensing pathway. The 2017 framework guidance and the post-2020 enforcement on unapproved stromal vascular fraction clinics have moved the boundary from a technical question into a sharp commercial one. Every new product line should re-test the four-prong analysis as part of design control.

Donor eligibility, look-back and adverse reaction: the cross-cutting spine

Whatever the path, the same four records must be defensible: the donor eligibility determination (medical history + physical + testing + signed determination as one record); the traceability chain donor-to-recipient and back; the look-back triggered by a post-donation positive test or recipient adverse outcome; and the deviation/adverse reaction report with its regulatory clock (15 days under §1271.350, BPDR under 21 CFR 606.171, AABB deviation reporting, EU SARE under 2004/23). Inspection findings here are inspection findings on every path — close them once and they close on all.

A 90-day multi-modality readiness path

Days 1–15: framework inventory — which paths your organisation actually runs, and where the overlays interact. Days 16–30: donor eligibility, traceability and deviation spine refresh (Path 8). Days 31–50: primary path internal audit (the path that owns your inspection). Days 51–70: secondary overlays — AABB, FACT-JACIE, EU 2004/23 — depending on product mix. Days 71–85: 361/351 boundary refresh across every product line. Days 86–90: integrated management review and inspection readiness rehearsal.

Standards covered in this guide

Each standard, retailer code or assurance scheme referenced above has its own deep-dive page with scope, audit detail and common pitfalls.

21 CFR 1271

FDA's framework for human tissue and cell products — registration, donor eligibility, current Good Tissue Practice, and the 361 / 351 line that separates allografts from full biologics licensure.

Donor eligibility

The formal, documented determination — risk assessment plus IDM testing — that a donor's blood or tissue donation may be released for clinical use.

Where this lives in V5 Ultimate

The clauses above aren't theoretical — every one maps to a shipped module and an industry profile. Jump to the parts of the product that turn this guide into evidence on a Monday morning.

Modules that do the work

Multi-framework QMS

One spine across 606, 1271, AABB, FACT, EU 2004/23.

Donor & traceability records

Donor-to-recipient chain on one record.

Deviation & SARE/BPDR

Right clock and form per framework overlay.

Industries this hits hardest

Blood & tissue

Frequently asked

We are a blood bank thinking about adding a cord blood line — what is the right starting path?

Path 1 (606/AABB) owns your existing inspection. Add Path 5 (cord blood) as an overlay. If you intend to license cord blood units under a BLA, you also pick up Path 2 (600/610). The donor eligibility and deviation spine (Path 8) is shared and does not need to be rebuilt.

We run a tissue bank — does the 2017 regenerative medicine framework apply to us?

If every product satisfies the four-prong test at §1271.10, you remain a Section 361 HCT/P establishment and CGTP applies. If any product fails one prong (typically minimal manipulation or homologous use), it moves to Section 351 and the GMP/IND/BLA path applies. The framework guidance is essentially a clarification of that boundary.

FACT-JACIE — is it required or voluntary?

Voluntary in the legal sense, but practically required by payers, transplant networks (NMDP/WMDA) and many commercial CAR-T sponsors as a condition of treating their products. Most US/EU cellular therapy centres maintain it.

Can one QMS really cover blood, tissue and CAR-T?

Yes — and it should. The donor eligibility, traceability, deviation, environmental monitoring and release records are structurally identical. What differs is the framework overlay (which form, which clock, which retention period). A QMS designed as one spine with overlays scales; a QMS designed as separate silos duplicates effort and breaks at the boundaries inspectors look at.

See it on your shop floor.

Free trial, no credit card, onboard in days, not months.

Start free trial See pricing →Browse all resources →